leisure time -WSS

leisure time

author：focus 2025-09-30 14:58:55 - browse：7189

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Bird flu makes raw milk dangerous to consume, mouse study finds

hotspot

WSS

Secretariat’s lessons for human medicine

Lawsuit challenges CMS nursing home minimum staffing rule

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

J&J reports mixed data on next

Achieving telehealth equity for people with hearing loss

Decentralized clinical trials need collaboration to achieve wider use

focus

leisure time

hotspot

Activists slam private health insurers over coverage restrictions

Weight loss drugs aren’t covered by Obamacare. That may change

Dobbs anniversary: the lost opportunity of abortion as health care

Decentralized clinical trials need collaboration to achieve wider use

What does generative AI mean for health care? We asked experts

The world needs the new pandemic treaty

Guidelines to prevent youth baseball injuries need more muscle

Secretariat’s lessons for human medicine

Medical records are filled with copy

Stroke rates rising, especially in working

hotspot

Flagship Pioneering startup Sonata Therapeutics lays off 21

New research sheds light on how often breast cancer is overdiagnosed

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Obamacare plans could cover weight loss drugs

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

J&J reports mixed data on next

explore

hotspot

knowledge

hotspot